ArcticZymes Technologies (AZT) Q2 2025 earnings summary

Executive summary

• Q2 2025 revenue increased 5% year-over-year to NOK 28.9 million, led by biomanufacturing and the launch of M-SAN HQ GMP, with EBITDA up 50% to NOK 3.9 million.

• Biomanufacturing became the main growth driver, contributing 68% of Q2 sales (NOK 18.1 million), up 52% year-over-year, with M-SAN HQ as the top-selling product.

• Diversified customer base reduced dependency on single accounts, though Molecular Tools saw a temporary 40% revenue decline due to a key customer, who has since returned.

• H1 2025 total revenue was NOK 53.8 million, down 7% year-over-year, reflecting a decline in Molecular Tools offset by biomanufacturing gains.

• Net profit for Q2 was NOK 3.3 million, up from NOK 2.7 million in Q2 2024.

Financial highlights

• Q2 sales revenue reached NOK 26.8 million, up 1% year-over-year; H1 sales were NOK 50 million, down 12–13% from last year.

• Total Q2 revenues, including other income, were NOK 28.9 million, up from NOK 27.5 million last year.

• EBITDA for Q2 was NOK 3.9 million (13.5–15% margin), up from NOK 2.6–2.76 million last year; H1 EBITDA was NOK 0.1 million, down from NOK 4.9 million.

• Cash and short-term investments stood at NOK 240–247 million at H1 end, with a Q2 increase of NOK 4.2 million and no debt.

• One-time loss of NOK 0.7 million on trade receivables recognized in Q2.

Outlook and guidance

• Continued long-term growth expected in biomanufacturing, especially in the U.S. and Europe, with recovery in Molecular Tools as key customers return.

• M-SAN HQ GMP launch anticipated to drive future growth and open new market segments.

• Strategic focus on expanding the enzyme portfolio for advanced therapies, next-generation sequencing, and metagenomics.

• No new enzyme launches planned for H2 2025; focus remains on market development and current portfolio.

• CDMO partnerships and new product development expected to support revenue normalization in H2 2025.